Patents Assigned to Medistem Labortories
  • Publication number: 20080260704
    Abstract: Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.
    Type: Application
    Filed: April 23, 2008
    Publication date: October 23, 2008
    Applicant: Medistem Labortories
    Inventors: Neil Riordan, Fabio Salazar, Thomas E. Ichim
  • Publication number: 20080260703
    Abstract: Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells.
    Type: Application
    Filed: April 23, 2008
    Publication date: October 23, 2008
    Applicant: Medistem Labortories
    Inventors: Neil Riordan, Tom Ichim
  • Publication number: 20080254005
    Abstract: Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.
    Type: Application
    Filed: April 5, 2008
    Publication date: October 16, 2008
    Applicant: Medistem Labortories
    Inventors: Neil H. Riordan, Thomas E. Ichim
  • Publication number: 20080159998
    Abstract: Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or manipulated in order to endow specific biological activity. Cellular subsets and administration of the subsets in combination with various agents are also provided. One embodiment teaches the previously unknown finding that adipose tissue derived mononuclear cells contain T cells with immune regulatory properties that alone or synergistically with various stem cells induce immune modulation upon administration. Another embodiment is the finding that stimulation of stem cell activation results in stem cell secondary activation of immune modulatory cells, one type which is T regulatory cells (Tregs).
    Type: Application
    Filed: December 18, 2007
    Publication date: July 3, 2008
    Applicant: Medistem Labortories
    Inventor: Thomas E. Ichim